stella
beta
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease — Stella
Home
/
Brain Cancer
/
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
View on ClinicalTrials.gov
Recruiting
Back to Brain Cancer trials
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Trial locations
(17 sites)
United States
City of Hope, Duarte, California
Miami Cancer Institute, Miami, Florida
North Georgia Health System, Gainesville, Georgia
Baptist Floyd, New Albany, Indiana
Baptist Corbin, Corbin, Kentucky
Baptist Hardin, Elizabethtown, Kentucky
Baptist Lexington, Lexington, Kentucky
Baptist Paducah, Paducah, Kentucky
Allina Health Cancer Institute, Minneapolis, Minnesota
Mayo Clinic, Rochester, Minnesota
Cleveland Clinic, Cleveland, Ohio
Oregon Health Sciences University, Portland, Oregon
Medical University of South Carolina, Charleston, South Carolina
McLeod Health, Florence, South Carolina
Baptist (BHMCC), Memphis, Tennessee
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Elligo Health Research, Inc., Austin, Texas